1-(3,4-dibenzyloxyphenyl)-2-aminopropane | 36593-29-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(3,4-dibenzyloxyphenyl)-2-aminopropane
• 英文别名: 1-(3,4-bis(benzyloxy)phenyl)propan-2-amine；(+/-)-1-(3,4-Dibenzyloxy-phenyl)-2-amino-propan；3,4-Dibenzyloxyphenylisopropylamin；(+/-)-2-<3,4-Dibenzyloxy-phenyl>-1-methyl-aethylamin；2-(3,4-dibenzyloxyphenyl)-isopropylamine；1-[3,4-Bis(phenylmethoxy)phenyl]propan-2-amine
• CAS: 36593-29-0
• 化学式: C₂₃H₂₅NO₂
• 分子量: 347.457
• InChiKey: FWGOAZLMDQEBAU-UHFFFAOYSA-N

物化性质

• 沸点：
  499.4±40.0 °C(Predicted)
• 密度：
  1.112±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  26
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  44.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(3,4-dibenzyloxyphenyl)-2-aminopropane 在 4-二甲氨基吡啶 、 三乙胺 、 O,O'-dibenzoyl-L-tartaric acid 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 6.0h， 生成 (S)-N-ethoxycarbonyl-1-(3,4-dibenzyloxyphenyl)-2-aminopropane
  参考文献：
  名称：

  Synthesis and capillary electrophoretic analysis of enantiomerically enriched reference standards of MDMA and its main metabolites

  摘要：

  Enantiomerically-enriched (S)-3,4-methylenedioxymethamphetamine (MDMA) and its main metabolites (S)-4-hydroxy-3-methoxymethamphetamine (HMMA) and (S)-3,4-dihydroxymethamphetamine (HHMA) were prepared for unequivocal identification of the differential enantioselective metabolism of these compounds as well as for its application in the analysis of biological samples. Capillary electrophoresis with cyclodextrin derivatives and a chemical correlation of (S)-MDMA. (S)-HMMA and (S)-HHMA has been performed to assign the absolute stereochemistry of major isomers in analytical standards enriched with such enantiomers. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(01)00367-4
• 作为产物：
  描述：

  3,4-二苄氧基苯甲醛 在 lithium aluminium tetrahydride 、 ammonium acetate 作用下， 以 四氢呋喃 为溶剂， 反应 21.0h， 生成 1-(3,4-dibenzyloxyphenyl)-2-aminopropane
  参考文献：
  名称：

  Synthesis and capillary electrophoretic analysis of enantiomerically enriched reference standards of MDMA and its main metabolites

  摘要：

  Enantiomerically-enriched (S)-3,4-methylenedioxymethamphetamine (MDMA) and its main metabolites (S)-4-hydroxy-3-methoxymethamphetamine (HMMA) and (S)-3,4-dihydroxymethamphetamine (HHMA) were prepared for unequivocal identification of the differential enantioselective metabolism of these compounds as well as for its application in the analysis of biological samples. Capillary electrophoresis with cyclodextrin derivatives and a chemical correlation of (S)-MDMA. (S)-HMMA and (S)-HHMA has been performed to assign the absolute stereochemistry of major isomers in analytical standards enriched with such enantiomers. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(01)00367-4

文献信息

• PIPERIDINE DERIVATIVE AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF
  申请人：Jiangsu Hengrui Medicine Co., Ltd.

  公开号：EP3312184A1

  公开（公告）日：2018-04-25

  The present invention relates to a piperidine derivative and the preparation method and a pharmaceutical use thereof. In particular, the present invention relates to the piperidine derivative as shown by general formula (I) and the preparation method thereof and a pharmaceutical composition containing same, and the use thereof as an estrogen receptor modulator in the treatment of estrogen receptor mediated or dependent diseases or conditions, the diseases particularly preferably being breast cancer. In the abstract, the definition of each substituent of the general formula (I) is the same as that in the description.

  本发明涉及一种哌啶衍生物及其制备方法和药物用途。特别是，本发明涉及通式（I）所示的哌啶衍生物及其制备方法和含有该衍生物的药物组合物，以及其作为雌激素受体调节剂在治疗雌激素受体介导或依赖性疾病或病症中的用途，该疾病特别优选为乳腺癌。在摘要中，通式（I）各取代基的定义与描述中的相同。
• Piperidine derivative and preparation method and pharmaceutical use thereof
  申请人：Jiangsu Hengrui Medicine Co., Ltd.

  公开号：US10385060B2

  公开（公告）日：2019-08-20

  The present invention relates to a piperidine derivative and the preparation method and a pharmaceutical use thereof. In particular, the present invention relates to the piperidine derivative as shown by general formula (I) and the preparation method thereof and a pharmaceutical composition containing the same, and the use thereof as an estrogen receptor modulator in the treatment of estrogen receptor mediated or dependent diseases or conditions, the diseases preferably being breast cancer. In the abstract, the definition of each substituent of the general formula (I) is the same as that in the description.

  本发明涉及一种哌啶衍生物及其制备方法和药物用途。特别是，本发明涉及通式（I）所示的哌啶衍生物及其制备方法和含有该衍生物的药物组合物，以及其作为雌激素受体调节剂在治疗雌激素受体介导或依赖性疾病或病症中的用途，该疾病优选为乳腺癌。在摘要中，通式（I）各取代基的定义与描述中的相同。
• [EN] PIPERIDINE DERIVATIVE AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF<br/>[FR] DÉRIVÉ PIPÉRIDINE ET SON PROCÉDÉ DE PRÉPARATION ET UTILISATION PHARMACEUTIQUE ASSOCIÉE<br/>[ZH] 哌啶类衍生物、其制备方法及其在医药上的应用
  申请人：JIANGSU HENGRUI MEDICINE CO

  公开号：WO2016202161A1

  公开（公告）日：2016-12-22

  本发明涉及哌啶类衍生物、其制备方法及其在医药上的应用。特别地，本发明涉及通式(I)所示的哌啶类衍生物、其制备方法及含有该衍生物的药物组合物，以及其作为雌激素受体调节剂治疗雌激素受体介导的或依赖性的疾病或病症的用途，所述的疾病特别优选乳腺癌。其中通式(I)的各取代基同说明书中的定义相同。
• PRATESI; LAMANNA; GRANA, Farmaco, Edizione Scientifica, 1964, vol. 19, p. 529 - 536
  作者：PRATESI、LAMANNA、GRANA

  DOI：——

  日期：——
• EP3312184
  申请人：——

  公开号：——

  公开（公告）日：——